Groundbreaking FDA Approval of GSK's RSV Vaccine for High-risk Age Group
Friday, 7 June 2024, 22:21
Groundbreaking FDA Approval of GSK's RSV Vaccine for High-risk Age Group
The FDA's approval of GSK's RSV vaccine for high-risk adults aged 50 to 59 is a significant milestone that will broaden the vaccine's impact. This move expands GSK's position in the competitive RSV market, challenging key players like Pfizer and Moderna. With this approval, GSK strengthens its hold in the market and secures a strategic advantage.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.